Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹2,479 Cr
Revenue (TTM)
₹868 Cr
Net Profit (TTM)
₹109 Cr
ROE
9 %
ROCE
12.3 %
P/E Ratio
22.7
P/B Ratio
2.1
Industry P/E
26.59
EV/EBITDA
10.8
Div. Yield
0.2 %
Debt to Equity
0.1
Book Value
₹109.4
EPS
₹10.5
Face value
1
Shares outstanding
105,788,972
CFO
₹949.20 Cr
EBITDA
₹1,456.17 Cr
Net Profit
₹869.08 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bliss GVS Pharma
| 43.3 | 10.4 | 44.5 | 96.3 | 48.8 | 18.4 | 5.9 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Bliss GVS Pharma
| -7.9 | 31.9 | 72.2 | -30.2 | -48.8 | 36.7 | -7.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bliss GVS Pharma
|
234.2 | 2,478.6 | 868.1 | 114.4 | 11.1 | 10.1 | 22.7 | 2.1 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 388.9 | 7,603.2 | 1,432.0 | 149.0 | 19.1 | 7.9 | 50.7 | 3.1 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Bliss GVS Pharma Limited engages in the development, manufacturing and marketing of pharmaceutical formulations in India and internationally. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral... suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotion, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, nasal inhalers, over-the-counter products, petroleum jellies, roll-ons, shampoo, soaps, sprays, and vaginal washes. In addition, it offers therapeutic products consisting of analgesics, antacids, anxiolytics, and haematinics; anti-bacterials, antibiotics, anti-diabetics, anti-diarrheals, anti-emetics, antifungals, anti-haemorrhoidals, anti-helmintics, anti-infectives, anti-inflammatories, anti-malarials, anti-microbials, anti-migraines, anti-oxidants, anti-protozoals, anti-pyretics, anti-septics, anti-spasmodics, anti-ulcers, and anti-ulcerants; cough syrups and nasal decongestants; and products for erectile dysfunction, laryngitis, and pharyngitis. Further, it provides and anti-dandruff shampoos, appetizers, hand sanitizers, health and nutritional supplements, insecticides, mosquito repellants, moisturizers, prickly heat powders, skin lightening lotions, vaginal contraceptives, vaginal hygiene products, and vitamin supplements; and amino acid preparations, iron tonics, antitussives, appetite stimulants, anti-allergics, body supplements, ear wax solvents, and oral rehydration products. The company exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India. Read more
Incorporated
1984
Chairman
Nandkumar chodankar
Managing Director
--
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Bliss GVS Pharma Ltd is ₹234.18 (NSE) and ₹234.30 (BSE) as of 02-Apr-2026 IST. Bliss GVS Pharma Ltd has given a return of 48.75% in the last 3 years.
The P/E ratio of Bliss GVS Pharma Ltd is 22.72 times as on 02-Apr-2026, a 15 discount to its peers’ median range of 26.59 times.
The P/B ratio of Bliss GVS Pharma Ltd is 2.14 times as on 02-Apr-2026, a 52 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
14.69
|
1.19
|
|
2024
|
15.63
|
1.23
|
|
2023
|
10.47
|
0.85
|
|
2022
|
53.04
|
0.99
|
|
2021
|
14.86
|
1.28
|
The 52-week high and low of Bliss GVS Pharma Ltd are Rs 243.90 and Rs 108.12 as of 04-Apr-2026.
Bliss GVS Pharma Ltd has a market capitalisation of ₹ 2,479 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Bliss GVS Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹4.78
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.